Sunshine Biopharma Inc. is a Colorado corporation headquartered in the greater Montreal area (Canada).
Adva-27a Anticancer Drug
Since inception, Sunshine Biopharma has been involved in the development of Adva-27a, a small molecule that has been shown to be exceptionally effective at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).
These and other preclinical results have been published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012. Adva-27a is the only compound known that is capable of destroying Multidrug Resistant Cancer Cells. The Company is planning to conduct Adva-27a Phase I Clinical Trials for Pancreatic Cancer indication at McGill University’s Jewish General Hospital in Montreal (Canada).
Sunshine Biopharma is a direct owner of all worldwide patents covering Adva-27a, including all issued and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029.
On May 22nd, 2020, Sunshine Biopharma filed a patent application covering inhibitors of the Coronavirus main release, Mpro. The company is currently developing these compounds as a treatment for COVID-19. It is anticipated that such treatment will be in the form of a Tablet or Gelcap which can be taken at home.
In 2018, Sunshine Biopharma completed the development of Essential 9™, the first in a line of essential micronutrients products that the Company is planning to launch. On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma to manufacture and sell the Essential 9™ product. Essential 9™ dietary supplement tablets contain a balanced formula of the 9 essential amino acids that the human body cannot make. Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Sunshine Biopharma’s Essential 9™ provides all 9 Essential Amino Acids in freeform and in the proportions recommended by Health Canada. Essential 9™ is available in the US on Amazon.com and in Canada on Amazon.ca.
Sunshine Biopharma has licensing agreements for the following four (4) generic prescription drugs:
– Anastrozole for treatment of Breast Cancer
– Letrozole for treatment of Breast Cancer
– Bicalutamide for treatment of Prostate Cancer
– Finasteride for treatment of BPH (Benign Prostatic Hyperplasia)
These drugs will be available in Canadian pharmacies soon.
Directors & Officers
Dr. Steve Slilaty
Chairman & CEO
Dr. Slilaty is an accomplished scientist and a highly skilled business executive. He received his Bachelor of Science degree in Genetics and Biochemistry from Cornell University and his Ph.D. in Molecular Biology & Biochemistry from the University of Arizona. He is currently President & CEO of Sunshine Biopharma and has an appointment as Adjunct Professor at Universite du Quebec. Dr. Slilaty is a leader in the bioscience industry and is referenced in editorials, reviews and textbooks. His extensive contributions to science included the discovery of a new class of enzymes (IUBMB Enzyme: EC 22.214.171.124) and the development of key technology for the Human Genome Project (TrueBlue Cloning System). With a passion for medicine, he founded three biotech companies and took one public. The company he took public, Genomics One Corporation reached a $1 billion market cap. At Sunshine Biopharma Dr. Slilaty is working with the same determination as he pioneers a path towards the discovery of groundbreaking drugs for the treatment of aggressive forms of cancer.
Mr. Camille Sebaaly
Director & CFO
Mr. Sebaaly has over 20 years of experience in engineering, development and commercialization of emerging technologies worldwide. Mr. Sebaaly was appointed as our Chief Financial Officer, Secretary and a Director of Sunshine Biopharma on October 15, 2009. Previously, he held a number of senior executive positions in various areas including, financial management, business development, project management and finance. As an executive and an entrepreneur, he combines expertise in strategic planning and finance with strong skills in business development and deal structure and negotiations. In addition, Mr. Sebaaly worked in operations, general management, investor relations, marketing and business development with an emphasis on international business and marketing of advanced technologies including hydrogen generation and energy saving. Mr. Sebaaly graduated from State University of New York at Buffalo with an Electrical and Computer Engineering Degree in 1987.
Dr. Abderrazzak Merzouki
Director & COO
Dr. Merzouki is an accomplished scientist with over 20 years of experience in virology and immunology. Dr. Merzouki obtained his Ph.D. in Virology and Immunology from Institut Armand-Frappier in Quebec and received his post-doctoral training at the University of British Columbia and the BC Center for Excellence in HIV/AIDS research. He was appointed as a Director and Chief Operating Officer of Sunshine Biopharma in February 2015. Dr. Merzouki has over 30 publications and 70 communications in various, highly respected scientific journals in the field of cellular and molecular biology. Prior to joining Sunshine, Dr. Merzouki worked at the Institute of Biomedical Engineering in the Department of Chemical Engineering at Ecole Polytechnique de Montreal, where he taught and acted as a senior scientist involved in the research and development of plasmid and siRNA-based therapies. He also worked in the area of gene therapy where he performed several preclinical studies for pharmaceutical companies involving the use of adenoviral vectors for cancer therapy and plasmid vectors for the treatment of peripheral arterial occlusions. Dr. Merzouki also has extensive expertise in the design of expression vectors, and the production and purification of recombinant proteins. He developed technologies for production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. In addition to his academic expertise, Dr. Merzouki has a strong worldwide network of business and financial relationships.
B F Borgers CPA PC
5400 West Cedar Avenue
Lakewood, Colorado 80226
Andrew I. Telsey, P.C.
12835 E. Arapahoe Road, Suite I-803
Centennial, Colorado 80112
The Directors of Sunshine Biopharma are committed to completely transparent Corporate Governance. In collaboration with our Auditors and Legal counsels, we have adopted specific guidelines to promote the interest of our shareholders and govern the corporation with the highest standards of integrity.
Sunshine Biopharma Inc.
6500 Trans-Canada Highway, 4th Floor
Pointe-Claire, Quebec H9R 0A5